Clinical Hematology Review: Highlights From NEJM, Blood and JCO Clinical Oncology News Unlike rituximab (Rituxan, Biogen Idec/Genentech), obinutuzumab has no black box warnings. True False; True or False. In a Phase II study published in The New England Journal of Medicine (NEJM), ponatinib (Iclusig, Ariad) showed clinically significant ... |
